VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS)(www.appliedneurosolutions.com), a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer’s disease (AD), today announced a US Patent, entitled “Novel Saitohin Gene and Uses of Same” (the “Patent”) was issued to Albert Einstein College of Medicine (AECOM). APNS has exclusive rights to this patent for use in Alzheimer’s disease and other neurodegenerative diseases, through its licensing agreements with AECOM. The inventors on the Patent are Dr. Peter Davies, APNS’s founding scientist, and Dr. Chris Conrad.
